Mosunetuzumab plus lenalidomide induction with or without mosunetuzumab maintenance shows high and durable responses in patients with previously untreated FL

ASH 2025

Lymphoma

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

EHA 2026

Lymphoma

frontMIND: Tafasitamab plus lenalidomide and R-CHOP improves PFS in previously untreated high-risk DLBCL

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

EHA 2026

Lymphoma

EPCORE FL-1: Epcoritamab plus lenalidomide and rituximab demonstrate consistent efficacy across high- and low-risk subgroups in R/R FL

CHICAGO 2026

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

CHICAGO 2026

Lymphoma

frontMIND: Adding tafasitamab plus lenalidomide to R-CHOP delays disease progression in patients with high-risk DLBCL

Multiple Myeloma (MM)

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

Lancet Haematol

Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J

doi: 10.1016/S2352-3026(25)00143-7

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

ESMO 2025

Breast Cancer

Related content

TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

frontMIND: Tafasitamab plus lenalidomide and R-CHOP improves PFS in previously untreated high-risk DLBCL

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

EPCORE FL-1: Epcoritamab plus lenalidomide and rituximab demonstrate consistent efficacy across high- and low-risk subgroups in R/R FL

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC

frontMIND: Adding tafasitamab plus lenalidomide to R-CHOP delays disease progression in patients with high-risk DLBCL

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM